Acute Ischemic Stroke Management Guidelines
Immediate Assessment and Stabilization
- Obtain a non‑contrast head CT immediately for every patient with suspected acute ischemic stroke to rule out intracranial hemorrhage and to determine eligibility for reperfusion therapy. (AHA/ASA guideline) 1
- Secure airway, breathing, and circulation; give supplemental oxygen only if peripheral saturation is <94 %. (AHA/ASA guideline) 1
- Perform a rapid NIH Stroke Scale (NIHSS) assessment in the emergency department. (AHA/ASA guideline) 1
- Check capillary blood glucose on arrival and treat hypoglycemia (<60 mg/dL) with intravenous dextrose before any other intervention. (AHA/ASA guideline; Level B) 1, 2, 3
- Correct hypotension and hypovolemia to keep mean arterial pressure > 70 mm Hg for adequate cerebral perfusion. (AHA/ASA guideline) 1, 4
- Do not delay imaging for laboratory results; obtain CBC, electrolytes, renal function, coagulation profile, and troponin after imaging. (AHA/ASA guideline) 1
- Obtain a 12‑lead ECG to identify atrial fibrillation or acute coronary syndrome. (AHA/ASA guideline) 1
- Blood‑glucose measurement is the only laboratory test that must be completed before administering alteplase. (AHA/ASA guideline) 1
Neuroimaging Protocol
- First‑line imaging is a non‑contrast CT of the head; it is mandatory to exclude intracranial hemorrhage. (AHA/ASA guideline) 1, 5
- Non‑contrast CT is preferred over MRI because it is faster and more widely available, minimizing treatment delays. (AHA/ASA guideline) 5
- For patients considered for mechanical thrombectomy, perform CTA from the aortic arch to the vertex immediately after the non‑contrast CT to identify large‑vessel occlusion. (AHA/ASA guideline) 1, 5
- When presentation is 6–24 h after last known well, obtain CT perfusion or MRI diffusion‑weighted imaging to assess core‑penumbra mismatch before deciding on reperfusion therapy. (AHA/ASA guideline) 1
Intravenous Alteplase (tPA)
Dosing and Administration
- Alteplase dose: 0.9 mg/kg (maximum 90 mg); give 10 % as an IV bolus over 1 min, then infuse the remaining 90 % over 60 min. (AHA/ASA guideline) 1, 2, 3
Time Windows and Eligibility
- 0–3 h window – Class I, Level A: all patients ≥18 y with a measurable neurological deficit are eligible, regardless of age or NIHSS severity. (AHA/ASA guideline) 2, 3, 6
- 3–4.5 h window – Class I, Level B‑R: same eligibility as 0–3 h, but exclude patients >80 y, those with combined diabetes + prior stroke, NIHSS > 25, or on oral anticoagulants (regardless of INR). (AHA/ASA guideline) 2, 3, 6
- 4.5–9 h extended window: alteplase may be given when advanced perfusion imaging shows a favorable core‑penumbra mismatch and thrombectomy is not planned. (AHA/ASA guideline) 1
- Wake‑up strokes: if MRI shows a DWI‑FLAIR mismatch, alteplase can be administered within 4.5 h of symptom recognition. (AHA/ASA guideline) 1
Blood‑Pressure Requirements
- Lower systolic/diastolic BP to <185/110 mm Hg before starting alteplase; maintain <180/105 mm Hg for the first 24 h after infusion. (AHA/ASA guideline) 1, 3, 6
- Use titratable IV agents (labetalol or nicardipine) for rapid BP control. (AHA/ASA guideline) 3
Imaging Eligibility Criteria
- No intracranial hemorrhage on CT/MRI. (AHA/ASA guideline) 3, 6
- Early ischemic changes must involve < 1/3 of the MCA territory; an ASPECTS ≥ 6 is required. (AHA/ASA guideline) 3, 6, 1
Absolute Contraindications
- Intracranial hemorrhage on imaging.
- Ischemic stroke within the prior 3 months.
- Severe head trauma within the prior 3 months.
- Unclear or unwitnessed onset > 4.5 h (unless DWI‑FLAIR mismatch present).
- Extensive hypodensity > 1/3 MCA territory on CT.
Post‑Alteplase Management
- Avoid all antithrombotic agents (aspirin, heparin, anticoagulants) for the first 24 h after alteplase. (AHA/ASA guideline) 3
- Monitor neurologic status every 15 min during infusion, then hourly for the next 6 h. (AHA/ASA guideline) 3
- Obtain an emergent repeat CT if the patient develops neurological deterioration, severe headache, or hypertensive spikes. (AHA/ASA guideline) 3
Mechanical Thrombectomy
- Indications (0–6 h): age ≥ 18 y, pre‑stroke mRS 0‑1, ICA or M1 occlusion on CTA, NIHSS ≥ 6, ASPECTS ≥ 6, and ability to achieve groin puncture ≤ 6 h from symptom onset. (AHA/ASA guideline) 1
- Extended window (6–24 h): anterior‑circulation large‑vessel occlusion with favorable advanced imaging (core‑penumbra mismatch, small core relative to clinical deficit). (AHA/ASA guideline) 1
- Do not wait for a response to alteplase before proceeding to angiography; thrombolysis and thrombectomy should be coordinated in parallel. (AHA/ASA guideline) 1
- Administer IV alteplase even when thrombectomy is planned (bridging therapy). (AHA/ASA guideline) 1
- Technical goal: achieve mTICI 2b/3 reperfusion. (AHA/ASA guideline) 1
Blood‑Pressure Management (Non‑Thrombolysis Patients)
- Adopt permissive hypertension; do not lower BP unless SBP > 220 mm Hg, DBP > 120 mm Hg, or there is concurrent acute MI, aortic dissection, or pre‑eclampsia/eclampsia. (AHA/ASA guideline) 3, 1
Glucose Management
- Target blood glucose 140–180 mg/dL during the first 24 h; persistent > 180 mg/dL is linked to worse outcomes and higher risk of hemorrhagic transformation. (AHA/ASA guideline; Level B) 2, 3
- Treat hypoglycemia (< 60 mg/dL) immediately with IV dextrose. (AHA/ASA guideline) 1, 2, 3
- Continuous glucose monitoring is recommended to avoid hypoglycemia, which can mimic stroke symptoms. (AHA/ASA guideline) 2, 3
Temperature Management
- Prevent fever (> 37.7 °C) using antipyretics and active cooling measures. (AHA/ASA guideline) 4, 2
- Continuous core‑temperature monitoring is advised. (AHA/ASA guideline) 4
- Therapeutic hypothermia is not recommended outside clinical trials because it raises pneumonia risk without proven benefit. (AHA/ASA guideline) 2, 3
Antiplatelet and Anticoagulation (Acute Phase)
- Do not give aspirin, clopidogrel, or any anticoagulant for the first 24 h after alteplase. (AHA/ASA guideline) 3
Special Situations
- Alteplase is contraindicated in patients receiving extracorporeal membrane oxygenation (ECMO) due to extreme bleeding risk with systemic anticoagulation. (AHA/ASA guideline) 4
- For ECMO patients with large‑vessel occlusion, consider mechanical thrombectomy after multidisciplinary discussion. (AHA/ASA guideline) 4
- Wake‑up stroke: use MRI DWI‑FLAIR mismatch to select patients for alteplase within 4.5 h of symptom recognition; if MRI is unavailable or mismatch absent, proceed directly to thrombectomy evaluation if within 24 h. (AHA/ASA guideline) 1
Common Pitfalls (What to Avoid)
- Never delay alteplase for “complete” laboratory results; only a bedside glucose check is required before treatment. (AHA/ASA guideline) 1
- Do not withhold alteplase from patients on single or dual antiplatelet therapy; the benefit outweighs the modest increase in hemorrhage risk. (AHA/ASA guideline) 6
Secondary Prevention Imaging
- Obtain CTA or MRA of the head and neck to detect carotid stenosis, arterial dissection, or other vascular pathologies after the acute phase. (AHA/ASA guideline) 1, 5
- Carotid duplex ultrasound is an acceptable alternative for evaluating extracranial carotid disease. (AHA/ASA guideline) 5
Acute Ischemic Stroke Management
Initial Assessment and Treatment
- The American Heart Association recommends immediate brain imaging with non-contrast CT or MRI to differentiate between ischemic and hemorrhagic stroke, followed by appropriate reperfusion therapy for eligible patients within their respective time windows 7, 8
- Perform rapid initial evaluation of airway, breathing, and circulation, and conduct neurological examination using a standardized stroke scale to determine focal deficits and assess stroke severity 9, 10
- Provide supplemental oxygen to maintain oxygen saturation ≥94% and correct hypotension and hypovolemia to maintain adequate systemic perfusion 8
Diagnostic Studies
- Perform immediate brain imaging with non-contrast CT or MRI, and consider CT angiography from arch-to-vertex for patients potentially eligible for endovascular therapy 8, 11, 12
- Obtain essential blood work, including blood glucose, complete blood count, serum electrolytes, and renal function, without delaying treatment 8, 9, 11
Acute Treatment
- Administer IV alteplase to eligible patients within 4.5 hours of symptom onset, with key eligibility criteria including measurable neurological deficit, no evidence of intracranial hemorrhage, and blood pressure <185/110 mmHg 8, 13
- Consider endovascular thrombectomy for patients with large vessel occlusion in the anterior circulation within 6 hours of symptom onset, and transfer patients to comprehensive stroke centers if EVT is indicated but unavailable 8, 12
Blood Pressure Management
- Lower blood pressure to <185/110 mmHg before thrombolysis, and maintain BP <180/105 mmHg for 24 hours after thrombolysis in patients eligible for thrombolysis 9, 10
- Consider lowering blood pressure only if systolic BP >220 mmHg or diastolic BP >120 mmHg in patients not eligible for thrombolysis, with a target 15-25% reduction within the first day 9, 10
Seizure Management
- Treat new-onset seizures at the time of stroke with short-acting medications, and do not use prophylactic anticonvulsants 9, 12
- A single, self-limiting seizure within 24 hours of stroke onset does not require long-term anticonvulsant medication 9, 12
Imaging and Acute Management in Suspected Stroke
Immediate Neuroimaging
- All patients with suspected acute stroke should receive an immediate non‑contrast CT (NCCT) of the head to rule out intracranial hemorrhage before any reperfusion therapy is started. 14
- NCCT is the preferred first‑line modality because it is widely available, rapidly excludes hemorrhage, and does not delay thrombolysis. 15, 16
- After NCCT, a CT angiography (CTA) from the aortic arch to the vertex should be performed in every patient who presents within 6 hours of symptom onset to detect large‑vessel occlusion (LVO) and guide endovascular therapy decisions. 14
- MRI with diffusion‑weighted imaging (DWI) may replace CT when it can be obtained without treatment delay; MRI is more sensitive for acute ischemia and posterior‑circulation strokes, though limited accessibility often restricts its hyperacute use. 15, 16
Blood‑Pressure Management Around Thrombolysis
- Aggressive lowering of blood pressure below recommended thresholds (≤185/110 mmHg before alteplase and ≤180/105 mmHg after) should be avoided because cerebral perfusion in acute stroke is pressure‑dependent and excessive reduction may worsen ischemia. 14
Contraindications to Intravenous Thrombolysis
- The presence of intracranial hemorrhage on imaging is an absolute contraindication to alteplase. 15
- A frank hypodensity on CT involving more than one‑third of the middle cerebral artery (MCA) territory constitutes a strong relative contraindication due to heightened risk of hemorrhagic transformation. 15
Seizure Management in Acute Stroke
- Acute seizures occurring at stroke onset should be treated promptly with a short‑acting benzodiazepine (e.g., lorazepam 2–4 mg IV) if the seizure does not terminate spontaneously. 14
- Routine prophylactic anticonvulsant therapy is not recommended; there is no evidence of benefit and it may impede neural recovery. 14
Mandatory Non‑Contrast CT Prior to Reperfusion Therapy in Acute Stroke
Immediate Transfer Protocol
- Activate emergency medical services and transport the patient without delay to the nearest stroke‑capable center that has a functioning CT scanner; brain imaging is required before any reperfusion therapy can be given. 17, 18
Imaging Requirements
- Non‑contrast CT is the single mandatory imaging study before intravenous thrombolysis or mechanical thrombectomy because it is needed to exclude intracranial hemorrhage, an absolute contraindication to alteplase and a determinant of subsequent management. 17, 18, 19, 20
- No reperfusion therapy (IV alteplase or mechanical thrombectomy) may be initiated without first ruling out hemorrhage on imaging. 18
- Administering thrombolytics to a patient with an unrecognized hemorrhagic stroke would be catastrophic; the mortality risk far outweighs any delay caused by transferring for imaging. 18
- Non‑contrast CT remains the preferred first‑line modality because it is faster, universally available, and reliably excludes hemorrhage—the most critical decision point before thrombolysis. 17, 20
- MRI can be considered at the receiving facility when CT findings are equivocal or for wake‑up strokes requiring DWI‑FLAIR mismatch assessment, but it must not postpone the initial treatment decision. 19
Blood‑Pressure Management
- For patients who may be eligible for thrombolysis (presentation ≤4.5 h), lower systolic/diastolic BP to < 185/110 mm Hg using intravenous labetalol (10–20 mg over 1–2 min) or a nicardipine infusion (starting 5 mg/h, titrated by 2.5 mg/h every 5–15 min, max 15 mg/h). 18
- If alteplase has already been administered at another facility, maintain BP < 180/105 mm Hg. 18
- For patients not eligible for thrombolysis, treat severe hypertension only when SBP > 220 mm Hg or DBP > 120 mm Hg, and reduce BP by 15–25 % over 24 h to avoid worsening cerebral ischemia. 17, 18
- Avoid lowering BP below the specified thresholds (< 185/110 mm Hg for thrombolysis candidates) because excessive reduction can compromise cerebral perfusion in the acute stroke setting. 17, 18
Seizure Management
- Treat active seizures with short‑acting benzodiazepines (e.g., lorazepam 2–4 mg IV); do not give prophylactic anticonvulsants, as they may impair neural recovery. 17